AOLS Stock Overview
A biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Aeolus Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.000001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | -99.90% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| AOLS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 3.4% | 1.6% |
| 1Y | n/a | 14.2% | 32.3% |
Return vs Industry: Insufficient data to determine how AOLS performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how AOLS performed against the US Market.
Price Volatility
| AOLS volatility | |
|---|---|
| AOLS Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AOLS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine AOLS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | n/a | John Mcmanus | www.aeoluspharma.com |
Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents.
Aeolus Pharmaceuticals, Inc. Fundamentals Summary
| AOLS fundamental statistics | |
|---|---|
| Market cap | US$152.00 |
| Earnings (TTM) | -US$4.09m |
| Revenue (TTM) | US$771.00k |
0.0x
P/S Ratio0.0x
P/E RatioIs AOLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AOLS income statement (TTM) | |
|---|---|
| Revenue | US$771.00k |
| Cost of Revenue | US$2.49m |
| Gross Profit | -US$1.72m |
| Other Expenses | US$2.37m |
| Earnings | -US$4.09m |
Last Reported Earnings
Jun 30, 2017
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did AOLS perform over the long term?
See historical performance and comparison